Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Actavis Inc    

ACTAVIS INC
Mes dernières consult.
Most popular
  Report  
SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
Latest news on ACTAVIS INC
02/05ALLERGAN : FDA Approves AVYCAZ for the Treatment of Patients with Hospital-Acqui..
AQ
02/05ALLERGAN : to Present at The Leerink Partners 7th Annual Global Healthcare Confe..
AQ
02/05ALLERGAN PLC : Change in Directors or Principal Officers (form 8-K)
AQ
02/05ALLERGAN : Matthew M. Walsh Appointed Executive Vice President and Chief Financi..
PR
02/03ALLERGAN : FDA Approves AVYCAZ (ceftazidime and avibactam) for the Treatment of ..
AQ
02/02ALLERGAN : completes restructuring, pushes hard in China
RE
02/02ALLERGAN : Introduces 'Not Cool vs. Cool' Multi-Channel Campaign for CoolSculpti..
AQ
02/02ALLERGAN : Introduces “Not Cool vs. Cool” Multi-Channel Campaign for..
AQ
02/01ALLERGAN : FDA Approves AVYCAZ® (ceftazidime and avibactam) for the Treatment of..
PR
02/01ALLERGAN : Trademark Application for "JUVEDERM" Filed by Allergan
AQ
02/01ALLERGAN : Trademark Application for "REFRESH FUSION TEARS REPAIR" Filed
AQ
02/01ALLERGAN : An Application for the Trademark "REFRESH FUSION REPAIR" Has Been Fil..
AQ
02/01ALLERGAN : An Application for the Trademark "ALLERGAN ACADEMY" Has Been Filed by..
AQ
02/01ALLERGAN : Trademark Application for "REFRESH TEARS REPAIR" Filed
AQ
02/01ALLERGAN : Trademark Application for "PATIENTS OUR VIRTUE" Filed
AQ
02/01ALLERGAN : to pay Israel's Teva Pharm $700 million to settle dispute
RE
02/01ALLERGAN PLC : Results of Operations and Financial Condition, Other Events (form..
AQ
01/31ALLERGAN : to Present at The Leerink Partners 7th Annual Global Healthcare Confe..
PR
01/31ALLERGAN INTRODUCES "NOT COOL VS. CO : Figure Skater Johnny Weir and Golfer Ian ..
PU
01/26OCULAR DRUG DELIVERY MARKET VOLUME A : Ocular Drug Delivery Market Overview & In..
AQ
01/25AMGEN : European Commission Approves Amgen And Allergan's MVASI® Biosimilar Beva..
AQ
01/23New York City sues drug companies over opioid epidemic
RE
01/22WILLIAM ACKMAN : Ackman cuts staff, shuns limelight as he seeks to turn around f..
RE
01/20ALLERGAN : Factory Mutual Insurance Co. Increases Holdings in Allergan plc (AGN)
AQ
01/19AMGEN : EC approves Amgen's biosimilar Avastin
AQ
01/18ALLERGAN : European Commission Approves Amgen And Allergan's MVASI® (Biosimilar ..
PR
01/17Ironwood and Allergan Announce Settlement with Sun Pharma Resolving LINZESS P..
AQ
01/17Allergan Pact Advances -- WSJ
DJ
01/17Judge Signals He Will Approve $290 Million Settlement Between Allergan Shareh..
DJ
01/16Judge Signals He Will Approve $290 Million Settlement Between Allergan Shareh..
DJ
01/16ALLERGAN : Ironwood and Allergan Announce Settlement with Sun Pharma Resolving L..
BU
01/13ALLERGAN : Evolus Files for IPO Ahead of Potential 2018 Approval for Botox Alter..
AQ
01/11ALLERGAN : Trademark Application for "NASH COUNSEL SUPPORT EDUCATION LEADERSHIP"..
AQ
01/11ALLERGAN : 2 Reasons Why Allergan Stock Plunged in 2017
AQ
01/09U.S. pharma executives expect deals to pick up after tax overhaul
RE
01/09ALLERGAN PLC (NYSE : AGN) Files An 8-K Results of Operations and Financial Condi..
AQ
01/08ALLERGAN PLC : Results of Operations and Financial Condition, Regulation FD Disc..
AQ
01/08ALLERGAN : Provides 2018 Preliminary Financial Outlook for Select Income Stateme..
PR
01/08ALLERGAN : to Report Fourth Quarter and Full Year 2017 Earnings and Host Confere..
PR
01/04ALLERGAN : Acknowledges Appeals Court Decision for COMBIGAN®
AQ
01/04ALLERGAN : to Present at the 36th Annual J.P. Morgan Healthcare Conference
AQ
01/04STUDIES FROM ALLERGAN UPDATE CURRENT : Timing and...
AQ
01/04ALLERGAN : Oculis raises CHF20M series B
AQ
01/03ALLERGAN : to cut over 1,000 jobs as it works to cut costs
RE
01/03ALLERGAN PLC : Results of Operations and Financial Condition, Regulation FD Disc..
AQ
01/03Pershing Square, Valeant to appear in court on insider trading suit settlemen..
RE
01/03Allergan among companies unveiling price hikes
AQ
01/03ALLERGAN PLC (NYSE : AGN) Files An 8-K Entry into a Material Definitive Agreemen..
AQ
01/03Pershing Square, Valeant to appear in court on insider trading suit settlemen..
RE
01/02ALLERGAN PLC : Entry into a Material Definitive Agreement, Material Modification..
AQ
2017Pershing Square, Valeant arrive at settlement split for Allergan lawsuit
RE
2017ALLERGAN : to Present at the 36th Annual J.P. Morgan Healthcare Conference
AQ
2017ALLERGAN : FDA Accepts New Drug Application For Seysara Sarecycline For The Trea..
AQ
2017ALLERGAN : Announces Promotion of Wayne Swanton to Executive Vice President, Glo..
AQ
2017ALLERGAN : and Richter Announce Positive Topline Results from Phase 3 Study of C..
AQ
2017ALLERGAN : Acknowledges Appeals Court Decision for COMBIGAN
AQ
2017ALLERGAN : to Present at the 36th Annual J.P. Morgan Healthcare Conference
PR
2017ALLERGAN : Acknowledges Appeals Court Decision for COMBIGAN®
PR
2017ALLERGAN : Succession doubts cloud Apotex future after billionaire owner's death
RE
2017ALLERGAN : Succession doubts cloud Apotex future after billionaire owner's death
RE
2017ALLERGAN : VISTABEL Receives Positive Opinion from ANSM for Treatment of Moderat..
AQ
2017ALLERGAN : FDA Accepts NDA For Acne Drug Seysara
AQ
2017ALLERGAN : Receives FDA Clearance For the CoolSculpting® Treatment To Improve Ap..
AQ
2017ALLERGAN : Announces Promotion of Wayne Swanton to Executive Vice President, Glo..
AQ
2017ALLERGAN : and Richter Announce Positive Topline Results from Phase 3 Study of C..
AQ
2017ALLERGAN : VISTABEL® (botulinum toxin type A) Receives Positive Opinion from ANS..
PU
2017ALLERGAN PLC (NYSE : AGN) Files An 8-K Departure of Directors or Certain Officer..
AQ
2017ALLERGAN PLC : Change in Directors or Principal Officers (form 8-K)
AQ
2017TEVA PHARMACEUTICAL INDUSTRIES : Union says workers at Israeli drugs firm Teva t..
RE
2017TEVA PHARMACEUTICAL INDUSTRIES : Union says workers at Israeli drugs firm Teva t..
RE
2017ALLERGAN : and Richter Announce Positive Topline Results from Phase 3 Study of C..
PR
2017ALLERGAN : Announces Promotion of Wayne Swanton to Executive Vice President, Glo..
PR
2017TEVA PHARMACEUTICAL INDUSTRIES : Strike over Teva Pharm job cuts briefly shuts d..
RE
2017ALLERGAN : Receives FDA Clearance for the CoolSculpting Treatment to Improve App..
AQ
2017TEVA PHARMACEUTICAL INDUSTRIES : Fears of Israeli job cuts at Teva sparks call f..
RE
Prev.1   2  3  4  5  6  7  8  9  10Next
Financials ($)
Sales 2018 15 225 M
EBIT 2018 7 285 M
Net income 2018 -908 M
Debt 2018 23 926 M
Yield 2018 1,84%
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 5,17x
EV / Sales 2019 4,83x
Capitalization 54 802 M
Chart ACTAVIS INC
Duration : Period :
Actavis Inc Technical Analysis Chart | US9426831031 | 4-Traders
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 208 $
Spread / Average Target 31%
EPS Revisions
Managers
NameTitle
Brenton L. Saunders Chairman, President & Chief Executive Officer
Wayne R. Swanton Executive Vice President-Global Operations
Matthew M. Walsh Chief Financial Officer & Executive Vice President
C. David Nicholson Chief Research & Development Officer
Paul M. Bisaro Director
Sector and Competitors
1st jan.Capitalization (M$)
ACTAVIS INC54 802
JOHNSON & JOHNSON-8.71%339 783
PFIZER0.86%217 897
NOVARTIS-7.67%204 972
ROCHE HOLDING LTD.-12.52%191 890
MERCK AND COMPANY4.55%158 571